Physician profile
Thomas Heigle
NPI 1174573711
$4,644.67
in general payments reported to CMS, 2019-2025
21 companies · $1,488 in 2025
The $1,488 reported for 2025 was more than what 85% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2020: $376 · 2021: $421 · 2022: $286 · 2023: $849 · 2024: $790 · 2025: $1,488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,127.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,316.61 | 2019-2025 | Clareon, Hydrus Microstent, Argos |
| Glaukos Corporation | $479.90 | 2020-2025 | Photrexa Viscous and Photrexa, Kxl1b-Ce-Marked Kxlsystem, Kxl System (Not Refurbished) |
| Biotissue Holdings INC. | $332.80 | 2022-2025 | |
| Abbvie INC. | $310.33 | 2024-2025 | |
| Oyster Point Pharma, INC. | $195.08 | 2022-2025 | Tyrvaya, Ryzumvi |
| Dompe US, INC. | $179.58 | 2019-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $177.99 | 2024-2025 | Xdemvy |
| Rxsight INC | $121.25 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Kala Pharmaceuticals, INC. | $120.48 | 2020-2021 | |
| Allergan, INC. | $106.21 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $54.22 | 2022-2023 | Flarex |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $41.56 | 2020-2021 | |
| Bausch & Lomb Americas INC. | $37.80 | 2023-2025 | Envista Mx60 Iol, Xiidra, Miebo |
| Sun Pharmaceutical Industries INC. | $33.42 | 2022-2025 | |
| Harrow Eye, LLC | $22.81 | 2025 | Vevye |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $22.51 | 2023 | Acthar |
| Ivantis, INC | $22.46 | 2020 | |
| Shire North American Group INC | $21.10 | 2019 | |
| Aerie Pharmaceuticals, INC. | $18.66 | 2021 | |
| Thea Pharma INC. | $15.49 | 2025 | Iyuzeh |
| Novartis Pharmaceuticals Corporation | $14.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Heigle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.